Berlin, January 2, 2002
Top Manager joins Mologen's Board of Directors
Mologen Holding AG announced today that Dr. Guido G.R. Sandler will join the company as Vice Chairman of the Board of Directors.
Dr. Sandler will be primarily responsible for the areas of financing, capital markets and investment management of Mologen.
Mologen develops and utilizes new gene-based technologies and products for preventing and curing diseases. The main focus of development is on the MIDGE technology, which has been patented by Mologen. MIDGE is the ideal tool for deploying genetic information safely and efficiently as a medicine.